Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRD1 | O95696 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939729 | 0.85 | VCAM1 (0.51) | TRPV4SLC22A12VCAM1 | |
| SCHEMBL1941288 | 0.84 | EPAS1 (0.41) | TRPV4SLC22A12VCAM1 | |
| SCHEMBL2893973 | 0.83 | EPAS1 (0.51) | TRPV4SLC22A12BRD4BRD1BRPF1 | |
| SCHEMBL23580400 | 0.83 | CA2 (0.56) | TRPV4SLC22A12VCAM1AR | |
| SCHEMBL16177963 | 0.82 | SLC22A12 (0.64) | SLC22A12AR | |
| SCHEMBL1156122 | 0.79 | TRPV4 (0.48) | TRPV4SLC22A12CYP11B2 | |
| SCHEMBL1396710 | 0.79 | CA2 (0.36) | TRPV4SLC22A12VCAM1 | |
| SCHEMBL31729379 | 0.79 | TRPV4 (0.48) | TRPV4SLC22A12CYP11B2 | |
| SCHEMBL1941568 | 0.79 | TSHR (0.41) | TRPV4SLC22A12VCAM1AR | |
| SCHEMBL30033471 | 0.79 | TSHR (0.41) | TRPV4SLC22A12VCAM1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| CN-111943889-B | Bis-aryl amine compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-07-22 | — | — | CN | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2009149819-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1963317-A1 | USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | TRPV4 1567/4885SLC22A12 3038/4885BRD4 1406/4885 |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | TRPV4 3643/4885SLC22A12 4623/4885BRD4 1614/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | TRPV4 2761/4885SLC22A12 2195/4885BRD4 159/4885 |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | TST, TBCA, TBCD | TRPV4 1910/4885SLC22A12 1257/4885BRD4 1186/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | TRPV4 41/4885SLC22A12 2148/4885BRD4 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.